NVSEF News and Press, Novartis Ag Basel Akt From 12/08/23

With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...

2023-12-06 10:11:00 ET More on TG Therapeutics TG Therapeutics: Trying To Fill The Gap Back To $20 TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript TG Therapeutics: Q3 Earnings Spike Hard To Explain Given Rival's Numbers TG Therapeutics gains aft...

Ad hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients 1- 5 In APPLY-PNH, patients who sw...

2023-12-05 13:28:55 ET More on Olema Pharmaceuticals Olema Pharmaceuticals: Advancing On Multiple Fronts Olema: Two-Pronged Approach To Treat Breast Cancer Patients Olema Pharmaceuticals officer discloses sale of about 10K shares Seeking Alpha’s Quant ...

2023-12-05 04:57:41 ET Summary Novartis has upgraded mid-term sales guidance to 5% CAGR until 2027. The core operating margin target is at 40%, and this implies a 6.5% upgrade in our EPS estimates. We are still concerned about sales post-2027 due to patent expirations. Therefo...

2023-12-04 15:35:38 ET More on Blackstone Blackstone: Short-Term Upside May Be Capped (Rating Downgrade) Blackstone Vs. Apollo: The Winner Might Shock You Bumble to repurchase stock, interests from Blackstone for $100M Blackstone raises $2.6B for eighth real ...

2023-12-02 02:24:45 ET Summary AbbVie has agreed to acquire ImmunoGen in a $10.1 billion all-cash deal, aiming to revitalize its struggling oncology operations. ImmunoGen's recent success with its drug ELAHERE, which received accelerated approval for the treatment of ovarian cance...

Late-breaking final iDFS analysis from NATALEE investigating Kisqali ® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with node-negative disease New 48-week efficacy and safety data from the Phase III ...

2023-11-19 09:56:29 ET Summary WisdomTree International Quality Dividend Growth Fund selects ex-North America dividend stocks with quality and expected earnings growth characteristics. The fund is well-diversified across countries, sectors, and holdings, with a focus on Europe. ...

2023-11-19 02:00:00 ET Summary Legend Biotech partners with Novartis in a $1.2 billion deal to develop and commercialize DLL3 CAR-T candidates. WuXi XDC, an ADC/bioconjugate CRDMO, raises $520 million in a successful IPO in Hong Kong. Shanghai SciClone Pharma acquires China ri...